April 20, 2021
Illumina's fight with the Federal Trade Commission over its $8 billion plan to buy cancer testing company Grail will take place in California federal court after a D.C. judge decided that a Golden State venue would be more convenient for witnesses.
April 09, 2021
The Federal Trade Commission urged a D.C. federal judge not to move its challenge to Illumina's planned $8 billion merger with Grail Inc., planned as a remote hearing before the D.C. district court, to California where in-person hearings are permitted, saying the move would trigger "undeniable risk" from COVID-19.
April 07, 2021
Illumina Inc. urged a D.C. federal judge to jettison the Federal Trade Commission's challenge to its planned $8 billion acquisition of Grail Inc., saying the deal can save numerous lives through advances in early cancer detection.
April 05, 2021
Illumina Inc. has urged a D.C. federal judge to send the Federal Trade Commission's suit challenging the biotech firm's planned $8 billion takeover of Grail Inc. to California, where the companies are based.
April 01, 2021
Illumina Inc. has agreed to delay closing its planned $8 billion acquisition of cancer detection firm Grail Inc. until as late as September while the Federal Trade Commission challenges the deal in D.C. federal court.